Hospital Universitario Fundación… · Institution

The Fundación Jiménez Díaz was founded in 1955 by the clinician Carlos Jiménez Díaz and is today a university hospital affiliated with the Universidad Autónoma de Madrid and managed within the Quirónsalud group under a public-private concession. Its cancer programme is organised as the OncoHealth Institute, integrating medical oncology, radiation oncology, haematology, surgical oncology and a large early-phase trials unit, and is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre. Research through the IIS-FJD health research institute covers lung and breast cancer, haematological malignancies and precision oncology.

Location

Madrid, ES

Type

hospital · Universidad Autónoma de Madrid

Website

www.fjd.es

Newsweek 2026 oncology rank

Not in top 300 listing used

OnCo score

#678 · 2 points (0 Newsweek + 0 NCI + 2 from 1 linked objects) · ranking

Research output

From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.

Matched to Hospital Universitario Fundación Jiménez Díaz, including child institutions. 523 works · 5,963 citations · 73% open access · 20% clinical trials · 0% reviews.

Oncology works per year

962022

1252023

1042024

1132025

852026

Most works

Most cited

Work	Journal	Year	Citations
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 10.1016/s0140-6736(25)01637-x · open access	The Lancet	2025	793
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study 10.1200/jco.22.01989 · open access	Journal of Clinical Oncology	2023	727
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer 10.1016/j.annonc.2023.05.008 · open access	Annals of Oncology	2023	314
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors 10.1001/jamanetworkopen.2023.41165 · open access	JAMA Network Open	2023	138
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial 10.1038/s41591-023-02696-8 · open access	Nature Medicine	2023	132
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial 10.1016/s2213-2600(22)00309-5 · open access	The Lancet Respiratory Medicine	2022	126
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors 10.1158/2159-8290.cd-23-1334 · open access	Cancer Discovery	2024	123
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study 10.1016/s1470-2045(23)00222-x · open access	The Lancet Oncology	2023	98
Overcoming tumor resistance mechanisms in CAR-NK cell therapy 10.3389/fimmu.2022.953849 · open access	Frontiers in Immunology	2022	95
Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study) 10.1016/j.annonc.2022.09.160 · open access	Annals of Oncology	2022	89
A Liquid Biopsy Signature for the Detection of Patients With Early-Onset Colorectal Cancer 10.1053/j.gastro.2022.06.089 · open access	Gastroenterology	2022	81
A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors 10.1126/scitranslmed.abp9229	Science Translational Medicine	2023	78
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials 10.1038/s41467-024-48479-8 · open access	Nature Communications	2024	75
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors 10.1007/s11912-022-01218-y	Current Oncology Reports	2022	72
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy 10.1136/jitc-2022-005320 · open access	Journal for ImmunoTherapy of Cancer	2022	68

Programmes

3top

OncoHealth Institute
Early-phase trials
Precision oncology

People

1top

Javier Arcos

Gerente (Chief Executive), Hospital Universitario Fundación Jiménez Díaz, Madrid

Hospital managementHealthcare quality

Physician and hospital manager who is Gerente of Hospital Universitario Fundación Jiménez Díaz, the Quirónsalud-run public university hospital in Madrid.

Connected

2top

Institution
University Medical Center Groningen Comprehensive Cancer Center
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
ASST Spedali Civili di Brescia
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
Trinity St James's Cancer Institute
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
Institut du Cancer Paris CARPEM, AP-HP Centre
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
Linköping University Hospital Cancer Center
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
Maastricht UMC+ Comprehensive Cancer Center
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
Institut Universitaire de Cancérologie AP-HP Sorbonne Université
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
Catalan Institute of Oncology (ICO)
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.

institutions

Organisation of European Cancer Institutes

people

Javier Arcos

Hospital Universitario Fundación Jiménez Díaz

Research output

Programmes

People

Connected

Similar pages

institutions

people

Hospital Universitario Fundación Jiménez Díaz

Research output

Programmes

People

Connected

Similar pages

institutions

people

Hospital Universitario Fundación Jiménez Díaz

Overview

Research output

Programmes

People

Connected

Similar pages

institutions

people

Hospital Universitario Fundación Jiménez Díaz

Overview

Research output

Programmes

People

Connected

Similar pages

institutions

people